← Issue №14/ week of Oct 4, 2026/Hepatology

A Markov model cost threshold analysis of potential hepatitis B virus cure regimens.

From GI Signals issue №14: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology meta analysis · Sep 28, 2026 · Clin Transl Gastro · IF 3.4

A Markov model cost threshold analysis of potential hepatitis B virus cure regimens.

New evidenceviral hepatitiscost-effectivenesshealth servicesepidemiology
Clinical takeawayNo clinical action yet: a modeling study projecting cost-effectiveness thresholds for a potential CHB cure regimen.
What it foundA 30% effective functional cure regimen for CHB could be cost-effective at a one-time treatment cost under USD46,642 in the U.S. and USD13,008 in China.
ContextThis analysis provides a framework for evaluating the cost-effectiveness of future CHB cure therapies compared to long-term NUC treatment, which is the current standard.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Wong GL … Yip TC · Clinical and Translational Gastroenterology · IF 3.4 · PubMed ↗Permalink
← Read the whole of issue №14 Every paper GI Signals surfaces gets a page like this one. All issues